Media coverage about Agilent Technologies (NYSE:A) has been trending somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Agilent Technologies earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave headlines about the medical research company an impact score of 44.9740835867773 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the headlines that may have impacted Accern’s rankings:
- Gene Editing Technologies Market to Represent Significant Revenue Growth 2017–2025 (sbwire.com)
- Here Are The Largest Companies in America With Zero Black People on Their Boards (blackenterprise.com)
- Agilent Technologies, Inc. (A) 19.54% off from 200- SMA – Voice Of Analysts (analystsbuzz.com)
- Should You Buy Agilent Technologies, Inc. (A) or Quest Diagnostics Incorporated (DGX)? – StockNewsGazette (stocknewsgazette.com)
- Microfluidic devices Market Major Influencing Key Players – Abbott, Agilent technologies, Inc, Bio-Rad Laboratories, Inc., Cepheid, Dolomite Centre (medgadget.com)
Several research analysts have recently issued reports on the company. BidaskClub downgraded Agilent Technologies from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 12th. Janney Montgomery Scott upped their price objective on Agilent Technologies from $65.00 to $70.00 and gave the company a “buy” rating in a research note on Wednesday, August 16th. J P Morgan Chase & Co reaffirmed an “overweight” rating and issued a $70.00 price objective on shares of Agilent Technologies in a research note on Wednesday, August 16th. Bank of America Corporation upped their price objective on Agilent Technologies from $66.00 to $68.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 16th. Finally, Morgan Stanley reaffirmed an “overweight” rating on shares of Agilent Technologies in a research note on Wednesday, August 16th. Three research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $63.91.
Shares of Agilent Technologies (A) opened at 65.02 on Monday. The company has a market capitalization of $20.94 billion, a PE ratio of 33.53 and a beta of 1.30. The company has a 50-day moving average price of $61.64 and a 200 day moving average price of $57.50. Agilent Technologies has a one year low of $42.92 and a one year high of $65.68.
Agilent Technologies (NYSE:A) last released its quarterly earnings results on Tuesday, August 15th. The medical research company reported $0.59 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.52 by $0.07. Agilent Technologies had a return on equity of 16.95% and a net margin of 14.36%. The company had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.09 billion. During the same period in the previous year, the company posted $0.49 earnings per share. The firm’s revenue was up 6.7% on a year-over-year basis. Equities analysts anticipate that Agilent Technologies will post $2.32 EPS for the current year.
In other Agilent Technologies news, insider Patrick Kaltenbach sold 5,000 shares of the business’s stock in a transaction on Thursday, July 13th. The stock was sold at an average price of $61.26, for a total value of $306,300.00. Following the sale, the insider now directly owns 45,138 shares of the company’s stock, valued at $2,765,153.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Boon Hwee Koh sold 4,500 shares of the business’s stock in a transaction on Wednesday, August 30th. The stock was sold at an average price of $63.63, for a total value of $286,335.00. The disclosure for this sale can be found here. Insiders have sold 141,098 shares of company stock worth $8,798,933 over the last 90 days.
WARNING: This story was published by Markets Daily and is owned by of Markets Daily. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://www.themarketsdaily.com/2017/09/11/agilent-technologies-a-receiving-somewhat-positive-press-coverage-study-shows.html.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.